Subscribe
shutterstock_742316485_chrisdorney
chrisdorney / Shutterstock.com
5 March 2020AmericasRory O'Neill

Gilead to face HIV antitrust claims

Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead hit with antitrust suit over HIV drugs
16 January 2020   Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Americas
US govt argues Gilead’s patent claims are ‘insufficient’
19 May 2020   The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.
Big Pharma
Gilead pays $1.25bn to GSK in HIV drug settlement
3 February 2022   Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Gilead hit with antitrust suit over HIV drugs
16 January 2020   Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Americas
US govt argues Gilead’s patent claims are ‘insufficient’
19 May 2020   The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.
Big Pharma
Gilead pays $1.25bn to GSK in HIV drug settlement
3 February 2022   Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents.

More on this story

Americas
Gilead hit with antitrust suit over HIV drugs
16 January 2020   Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Americas
US govt argues Gilead’s patent claims are ‘insufficient’
19 May 2020   The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.
Big Pharma
Gilead pays $1.25bn to GSK in HIV drug settlement
3 February 2022   Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility